Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Debt: 2009-2013

Historic Non-Current Debt for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2013 value amounting to $283,000.

  • Gyre Therapeutics' Non-Current Debt fell 84.53% to $142,000 in Q1 2014 from the same period last year, while for Mar 2014 it was $142,000, marking a year-over-year decrease of 84.53%. This contributed to the annual value of $283,000 for FY2013, which is 75.09% down from last year.
  • Per Gyre Therapeutics' latest filing, its Non-Current Debt stood at $283,000 for FY2013, which was down 75.09% from $1.1 million recorded in FY2012.
  • Over the past 5 years, Gyre Therapeutics' Non-Current Debt peaked at $2.0 million during FY2011, and registered a low of $283,000 during FY2013.
  • Moreover, its 3-year median value for Non-Current Debt was $1.1 million (2012), whereas its average is $1.1 million.
  • In the last 5 years, Gyre Therapeutics' Non-Current Debt soared by 47.22% in 2011 and then tumbled by 75.09% in 2013.
  • Gyre Therapeutics' Non-Current Debt (Yearly) stood at $2.0 million in 2009, then crashed by 31.38% to $1.3 million in 2010, then spiked by 47.22% to $2.0 million in 2011, then plummeted by 42.80% to $1.1 million in 2012, then plummeted by 75.09% to $283,000 in 2013.